From Department of Cardiology, University Heart Center (T.F.L., U.L.), and Department of Clinical Chemistry (A.v.E.), University Hospital Zurich, Zurich, Switzerland; Division of Cardiovascular Research, Institute of Physiology, University of Zurich, Zurich, Switzerland (T.F.L., U.L.); and Department of Medicine, University of California, Los Angeles, CA (A.M.F.).
Circ Res. 2014 Jan 3;114(1):171-82. doi: 10.1161/CIRCRESAHA.114.300935.
High-density lipoprotein (HDL) is a complex mixture of lipoproteins that is associated with many minor proteins and lipids that influence the function of HDL. Although HDL is a promising marker and potential therapeutic target based on its epidemiological data and the effects of healthy HDL in vitro in endothelial cells and macrophages, as well as based on infusion studies of reconstituted HDL in patients with hypercholesterolemia, it remains still uncertain whether or not HDL cholesterol-raising drugs will improve outcomes. Recent studies suggest that HDL becomes modified in patients with coronary artery disease or acute coronary syndrome because of oxidative processes that result in alterations in its proteome composition (proteome remodelling) leading to HDL dysfunction.
高密度脂蛋白（HDL）是一种脂蛋白的复杂混合物，与许多影响 HDL 功能的少量蛋白质和脂质有关。尽管基于其流行病学数据以及健康的 HDL 在体外对内皮细胞和巨噬细胞的作用，以及在高胆固醇血症患者中输注重组 HDL 的研究结果，HDL 作为一种有前途的标志物和潜在的治疗靶点，但仍不确定升高 HDL 胆固醇的药物是否会改善预后。最近的研究表明，由于氧化过程导致其蛋白质组组成发生改变（蛋白质组重塑），导致 HDL 功能障碍，因此在患有冠状动脉疾病或急性冠状动脉综合征的患者中，HDL 会发生修饰。
Zotero 插件